novo nordisk oral glp-1 Wins EU Approval for First Weight-Loss Drug Wegovy Novo Nordisk's oral GLP-1 drug
Description
GLP-1s offer treatment for diabetes, obesity, heart disease and morebut there are caveats
A public health expert explains how GLP-1 drugs have changed the way healthcare providers understand and treat obesity.
Not intended for individuals under 18, pregnant or nursing individuals, or anyone with a known medical condition or taking medication including GLP-1 medications
Combining GLP-1 medications like semaglutide with antidepressants such as bupropion requires medical oversight
Includes PREDIMED data and EU health claim context.
Learn how GLP-1 medications like Semaglutide and Tirzepatide support weight loss
